title: SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.
abstract: By using GRADE system we updated the guidelines for management of CLL issued in 2006 from SIE, SIES and GITMO group. We recommended fludarabine, cyclophosphamide, rituximab (FCR) in younger and selected older patients with a good fitness status, no unfavourable genetics (deletion 17p and/or p53 mutations), and a less toxic treatment in nonfit and elderly patients. In patients without unfavourable genetics, relapsed after 24 months the same initial treatment including rituximab can be considered. In patients with unfavourable genetics, refractory or relapsed within 24 months from a prior fludarabine-based treatment, allogeneic SCT or experimental treatments should be given.
authors: Dipartimento di Biotecnologie Cellulari ed Ematologia, Università degli Studi La Sapienza, Roma, Italy.
authors: Francesca Romana
authors: FR
authors: Mauro
authors: Giuseppe
authors: G
authors: Bandini
authors: Giovanni
authors: G
authors: Barosi
authors: Atto
authors: A
authors: Billio
authors: Maura
authors: M
authors: Brugiatelli
authors: Antonio
authors: A
authors: Cuneo
authors: Francesco
authors: F
authors: Lauria
authors: Vincenzo
authors: V
authors: Liso
authors: Monia
authors: M
authors: Marchetti
authors: Giovanna
authors: G
authors: Meloni
authors: Marco
authors: M
authors: Montillo
authors: Pierluigi
authors: P
authors: Zinzani
authors: Sante
authors: S
authors: Tura
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*